Gray, M. J., Gong, J., Hatch, M. M. S., Nguyen, V., Hughes, C. C. W., Hutchins, J. T., & Freimark, B. D. (2016). Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. Breast Cancer Res.

Gray, Michael J., Jian Gong, Michaela M. S. Hatch, Van Nguyen, Christopher C. W. Hughes, Jeff T. Hutchins, and Bruce D. Freimark. "Phosphatidylserine-targeting Antibodies Augment the Anti-tumorigenic Activity of Anti-PD-1 Therapy By Enhancing Immune Activation and Downregulating Pro-oncogenic Factors Induced By T-cell Checkpoint Inhibition in Murine Triple-negative Breast Cancers." Breast Cancer Res 2016.

Gray, Michael J., et al. "Phosphatidylserine-targeting Antibodies Augment the Anti-tumorigenic Activity of Anti-PD-1 Therapy By Enhancing Immune Activation and Downregulating Pro-oncogenic Factors Induced By T-cell Checkpoint Inhibition in Murine Triple-negative Breast Cancers." Breast Cancer Res 2016.